Business Description
HilleVax Inc
NAICS : 541714
SIC : 2834
ISIN : US43157M1027
Description
HilleVax Inc is a clinical-stage biopharmaceutical company. The company is focused on developing and commercializing novel vaccines. The firm's initial program, HIL-214, is a virus-like particle (VLP) based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis (AGE) caused by norovirus infection.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 5.48 | |||||
| Equity-to-Asset | 0.76 | |||||
| Debt-to-Equity | 0.22 | |||||
| Debt-to-EBITDA | -0.37 | |||||
| Piotroski F-Score | 2/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | -184.7 | |||||
| 3-Year EPS without NRI Growth Rate | -186.7 | |||||
| 3-Year FCF Growth Rate | -213.4 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 26.87 | |||||
| 9-Day RSI | 37.56 | |||||
| 14-Day RSI | 41.52 | |||||
| 6-1 Month Momentum % | -9.5 | |||||
| 12-1 Month Momentum % | -20.38 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 10.92 | |||||
| Quick Ratio | 10.92 | |||||
| Cash Ratio | 10.92 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -43 | |||||
| Shareholder Yield % | -5.31 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -56.73 | |||||
| ROA % | -44.48 | |||||
| ROIC % | -396.9 | |||||
| ROC (Joel Greenblatt) % | -448.75 | |||||
| ROCE % | -46.9 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 2.65 | |||||
| Price-to-Tangible-Book | 2.65 | |||||
| EV-to-EBIT | -2.92 | |||||
| EV-to-EBITDA | -2.97 | |||||
| EV-to-FCF | -3.27 | |||||
| Price-to-Net-Current-Asset-Value | 3.07 | |||||
| Price-to-Net-Cash | 3.07 | |||||
| Earnings Yield (Greenblatt) % | -34.25 | |||||
| FCF Yield % | -19.59 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:HLVX
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
HilleVax Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -3.3 | ||
| Beta | 0 | ||
| Volatility % | 60.84 | ||
| 14-Day RSI | 41.52 | ||
| 14-Day ATR ($) | 1.002829 | ||
| 20-Day SMA ($) | 13.954 | ||
| 12-1 Month Momentum % | -20.38 | ||
| 52-Week Range ($) | 9.94 - 20.22 | ||
| Shares Outstanding (Mil) | 49.72 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
HilleVax Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
HilleVax Inc Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
HilleVax Inc Frequently Asked Questions
What is HilleVax Inc(HLVX)'s stock price today?
The current price of HLVX is $12.89. The 52 week high of HLVX is $20.22 and 52 week low is $9.94.
When is next earnings date of HilleVax Inc(HLVX)?
The next earnings date of HilleVax Inc(HLVX) is 2024-08-14 Est..
Does HilleVax Inc(HLVX) pay dividends? If so, how much?
HilleVax Inc(HLVX) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers